Home » Stocks » MGNX

MacroGenics, Inc. (MGNX)

Stock Price: $25.01 USD 3.13 (14.31%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 1.39B
Revenue (ttm) 104.88M
Net Income (ttm) -129.74M
Shares Out 52.44M
EPS (ttm) -2.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $25.01
Previous Close $21.88
Change ($) 3.13
Change (%) 14.31%
Day's Open 22.03
Day's Range 22.03 - 25.80
Day's Volume 2,363,463
52-Week Range 4.04 - 32.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

ROCKVILLE, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based t...

GlobeNewsWire - 1 week ago

ROCKVILLE, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based ...

GlobeNewsWire - 2 weeks ago

ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based t...

GlobeNewsWire - 2 weeks ago

ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based t...

GlobeNewsWire - 2 weeks ago

ROCKVILLE, MD, Feb. 08, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based ...

The Motley Fool - 1 month ago

The company published data from a late-stage study of its promising breast cancer drug.

GlobeNewsWire - 1 month ago

ROCKVILLE, MD, Jan. 25, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based th...

GlobeNewsWire - 1 month ago

ROCKVILLE, MD, Jan. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based t...

GlobeNewsWire - 2 months ago

PD-1 × CTLA-4 Bispecific DART® molecule is preliminarily well-tolerated in dose escalation clinical study PD-1 × CTLA-4 Bispecific DART® molecule is preliminarily well-tolerated in dose escala...

GlobeNewsWire - 2 months ago

ROCKVILLE, MD, Dec. 18, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based ...

The Motley Fool - 2 months ago

There were different reactions to the company's first FDA approval.

GlobeNewsWire - 2 months ago

ROCKVILLE, MD, Dec. 16, 2020 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based t...

GlobeNewsWire - 2 months ago

ROCKVILLE, MD, Dec. 07, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal anti...

GlobeNewsWire - 2 months ago

ROCKVILLE, MD, Dec. 06, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal anti...

GlobeNewsWire - 2 months ago

ROCKVILLE, MD and CHICAGO, IL, Nov. 30, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative...

GlobeNewsWire - 2 months ago

ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal anti...

Seeking Alpha - 3 months ago

MacroGenics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for immune-response modulation for treating cancer. MacroGenics's pipeline consists ...

GlobeNewsWire - 3 months ago

ROCKVILLE, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal anti...

Seeking Alpha - 3 months ago

MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

MacroGenics (MGNX) delivered earnings and revenue surprises of 28.26% and 77.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

Conference call scheduled for today at 4:30 p.m. ET. Conference call scheduled for today at 4:30 p.m. ET.

GlobeNewsWire - 3 months ago

ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibo...

GlobeNewsWire - 3 months ago

ROCKVILLE, MD, Oct. 28, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal anti...

Zacks Investment Research - 3 months ago

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

— Role of TP53 abnormalities in immunotherapy response in AML highlighted — Role of TP53 abnormalities in immunotherapy response in AML highlighted

GlobeNewsWire - 5 months ago

ROCKVILLE, MD, Sept. 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal an...

GlobeNewsWire - 5 months ago

ROCKVILLE, MD, Sept. 22, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal a...

GlobeNewsWire - 5 months ago

ROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal an...

GlobeNewsWire - 5 months ago

ROCKVILLE, MD, Sept. 20, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal an...

Seeking Alpha - 6 months ago

MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

MacroGenics (MGNX) delivered earnings and revenue surprises of -6.82% and 42.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

Conference call scheduled for today at 4:30 p.m. ET. Conference call scheduled for today at 4:30 p.m. ET.

GlobeNewsWire - 7 months ago

Rockville, MD, July 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal ant...

Zacks Investment Research - 7 months ago

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

Rockville, MD, July 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal ant...

The Motley Fool - 7 months ago

Investors remain optimistic that the leading drug candidate can earn marketing approval before the end of the year.

GlobeNewsWire - 8 months ago

Rockville, MD, June 16, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal ant...

Benzinga - 8 months ago

MacroGenics Inc (NASDAQ: MGNX) shares are moving on Friday. The company announced the FDA has granted Orphan Drug Designation to Margetuximab in the U.S.

GlobeNewsWire - 8 months ago

Rockville, MD, June 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal ant...

GlobeNewsWire - 8 months ago

Rockville, MD, June 03, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal ant...

The Motley Fool - 8 months ago

Traders are exiting the stock as the ASCO 2020 conference gets underway.

GlobeNewsWire - 8 months ago

- Advisory committee meeting not required; PDUFA goal date unchanged

GlobeNewsWire - 9 months ago

Rockville, MD, May 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal anti...

Benzinga - 9 months ago

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe.

Other stocks mentioned: ALLO, AMGN, ARVN, CTMX
GlobeNewsWire - 9 months ago

Rockville, MD, May 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal anti...

Zacks Investment Research - 9 months ago

Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.

The Motley Fool - 9 months ago

Optimism is growing ahead of the release of abstracts this week for the upcoming ASCO 2020 conference.

GuruFocus - 9 months ago

The price of MacroGenics Inc. (MGNX) shares has recently seen a huge jump. After providing an early glimpse of some of the earnings results on May 6, MacroGenics’s stock soared by more than 23...

The Motley Fool - 9 months ago

Here's what's behind their impressive market performances.

Other stocks mentioned: PTGX, STML
The Motley Fool - 9 months ago

The company could receive an FDA go-ahead on its lead drug candidate as soon as this year.

About MGNX

MacroGenics, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targetin... [Read more...]

Industry
Biotechnology
IPO Date
Oct 10, 2013
CEO
Scott Koenig
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
MGNX
Full Company Profile

Financial Performance

In 2020, MacroGenics's revenue was $104.88 million, an increase of 63.40% compared to the previous year's $64.19 million. Losses were -$129.74 million, -14.54% less than in 2019.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for MacroGenics stock is "Buy." The 12-month stock price forecast is 30.90, which is an increase of 23.55% from the latest price.

Price Target
$30.90
(23.55% upside)
Analyst Consensus: Buy